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Treatment of the injured joint with rhPRG4 is based on recent observations that
inflammation diminishes expression of native PRG4. Re-establishing lubrication between
pressurized and sliding cartilage surfaces during locomotion promotes the nascent
expression of PRG4 and thus intra-articular (IA) treatment strategies should be supported
by pharmacokinetic evidence establishing the residence time of rhPRG4. A total of 21
Yucatan minipigs weighing ~55 Kg each received 4 mg of 131I-rhPRG4 delivered by IA
injection 5 days following surgical ACL transection. Animals were sequentially euthanized
following IA rhPRG4 at 10 mins (time zero), 24, 72 hrs, 6, 13 and 20 days later. The decay
of the 131I-rhPRG4 was measured relative to a non-injected aliquot and normalized to the
weight of cartilage samples, menisci and synovium, and known cartilage volumes from
each compartment surface obtained from representative Yucatan minipig knees. Decay
of 131I-rhPRG4 from joint tissues best fit a two-compartment model with an  half-life (t1/2)
of 11.28 hours andhalf-lifet1/2) of 4.81 days. The tibial and femoral cartilage, meniscii
and synovium retained 7.7% of dose at 24 hrs. High concentrations of rhPRG4 were found
in synovial fluid (SF) that was non-aspiratable and resided on the articular surfaces,
removable by irrigation, at 10 mins following 131I-rhPRG4 injection. Synovial fluid K21
exceeded K12 and SF t1/2 was 28 days indicating SF is the reservoir for rhPRG4 following
IA injection. Clinical Significance: rhPRG4 following IA delivery in a traumatized joint
populates articular surfaces for a considerable period and may promote the native
expression of PRG4. This article is protected by copyright. All rights reserved

Keywords: Lubricin, PRG4, Pharmacokinetics, Half-life, Cartilage, Joint, ACL Transection
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Introduction

Osteoarthritis (OA) 1leads to functional disability and a reduced quality of life2.

Abnormal biomechanics is a major risk factor in disease progression and joint tissue damage3.

Post-traumatic osteoarthritis (PTOA) is a syndrome of joint degeneration and pain that develops

after joint injuries4; 5. Treating joint pain alone may actually exacerbate PTOA7; 8 since the pain
response is adaptively interfering with locomotion, and unloading the affected joint. New
therapeutic approaches that mitigate the risk of developing PTOA, particularly for young patients
with meniscal and anterior cruciate ligament (ACL) tears6 are needed.
Five different research groups have tested native9, recombinant human lubricin

(rhPRG4)10-12 or lubricin mimic biomolecules13; 14 by re-introducing these into rodent joints after
injury in the effort to retard cartilage loss. The inflammation associated with meniscal and ACL
injuries is thought to downregulate PRG4 expression15;

16

.

Rats that underwent medial

meniscectomy11 or ACL transection9; 17 treated with repeated or single dose intra-articular (IA)
rhPRG410 showed a chondroprotective effects measured by improved histology. Two studies
showed a reduction in urine levels of CTX-II—a classical biomarker of cartilage degradation10; 17.
Another study in ACL transected rat knees showed an improvement in the radiographic outcome

following supplementation with lubricin18. Chondroprotective results were also evident in rats that
underwent forced exercise17 and in mice where a helper-dependent adeno viral vector expressing

Prg4 prevented development of PTOA in mice19. Most recently we showed in large animals
following destabilization of the medial meniscus (DMM)12 that chondral lesions were smaller and
synovial fluid (SF) CTX-II levels were significantly lower, 5.5 months later following IA rhPRG4.
Lubricin supplementation decreases the number of apoptotic chondrocytes17; 20; 21 and increases
4
This article is protected by copyright. All rights reserved

native lubricin expression10. Elevated joint friction in Prg4 null mice22 also showed diminished
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chondrocyte density23. A concern about lubricin supplementation is whether rhPRG4 has a
favorable pharmacokinetic profile that would lead to its continued presence and enable tribological
protection.

The half-life of radiolabeled truncated lubricin is 4.5 hours in a medial meniscectomized

rat24. However, this value must be reconciled with radioactivity still present on the articular surface

up to 28 days following IA injection. Lubricin persists in traumatized cartilage25 and contributes

to protect joints from mechanical injury and may mitigate PTOA. Our current focus is to gather
data in a large animal model, particularly at early time points in an injury model, to enable
pharmacokinetic modeling that will be predictive of lubricin residence time in the human knee by
allometric scaling26. Transection of the ACL was chosen in a large animal model in this study since
lubricin levels in patients with an untreated ACL injury require a year to return to normal27 and
leads to an aggressive PTOA, dependent on early alterations in the cartilage matrix28.

METHODS
Animals
The study was conducted at University of Guelph, Ontario, Canada and used purpose-bred
castrated male and female Yucatan mini-pigs (N=21) weighing 50-60 kg. All porcine were

adolescent animals, born within 2 weeks of each other and were 9 months old at study conclusion.

Each animal underwent hematological, physical and musculoskeletal examinations upon arrival
from S&S Farms (Ramona, CA). Seven (7) days were permitted for acclimatization prior to
5

This article is protected by copyright. All rights reserved

surgery during which the animals were housed in pairs or small groups depending on behavior.
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Animals were maintained in controlled environmental facilities at 20oC and light/dark cycle
determined by ambient lighting. The study protocol was approved by the institutional animal care
and use committee and conducted in accordance with the Canadian Council on Animal Care
guidelines.
Manufacture of rhPRG4
The expression of rhPRG4 by CHO-M cells has been described previously29. CHO-M cells were

transfected with the full-length human PRG4 gene resulting in a 1404 amino acid PRG4 (Lubris,
LLC, Framingham, MA). Manufacturing was performed by Peregrine Pharmaceuticals, Inc.,
Tustin, CA) under pre-GMP conditions. The presence of O-linked glycosylations comprised of
(β1,3)Gal-GalNAc was previously confirmed by Western blot30;

31

and concentration was

established by ELISA31.
Labelling of rhPRG4 with 131I

rhPRG4 was radiolabelled with

131

I in 0.1M NaOH (Perkin Elmer Health Science, Canada, Inc)

using the iodine monochloride method. Radiolabelled rhPRG4 was passed through a column
containing AG1-X4 resin (Bio-Rad, Hercules, CA) to remove free

131

I. The trichloroacetic acid

test was performed to determine unbound 131I in the solution which did not exceed 8% (w/w). Vials
containing 4 mg of 131I-rhPRG4 in 3 ml PBS carrier with 32 Ci radioactivity were prepared for
animal injection.

6
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Surgical and Anesthesia Procedures
Using general anesthesia and aseptic technique mini-pigs underwent arthroscopic ACL ligament
transection of the right knee joint followed by the IA administration of 4 mg of 131I-rhPRG4 5 days
later. At the time of arthroscopy joint cavity irrigation was limited to 120 ml of sterile physiologic
saline. Radiolabeling of rhPRG4 (Lubris, LLC) was performed at McMaster University, and sent
the same day by courier to Ontario Veterinary College, University of Guelph. The

131

I-rhPRG4

was used within the day of arrival. The left knee was unaffected. There were no uninjected surgical

control animals.
On the day of the surgery porcine were pre-medicated with acepromazine (0.2 mg/kg), atropine
(0.05 mg/kg) and buprenorphine (0.02 mg/kg) given intramuscularly (IM). Anaesthesia was
induced with ketamine (20 mg/kg) and mask-ventilated (or intubated with an endotracheal tube)
with a 2% isoﬂurane O2 mixture. Aspiration of SF from both knees was attempted prior to surgical
entry of the joint. Postoperative analgesia consisted of peri-articular subcutaneous (sc) injection

of diluted bupivacaine (0.25%, 0.05-0.1 mL, dose < 1 mg/kg) and sc buprenorphine (0.05 to 0.1
mg/kg) every 4-6 hours as needed for up to 72 hours.
On day 5 post-surgery (designated D=0) all 21 pigs were sedated with acepromazine (0.2 mg/kg)
and ketamine (20 mg/kg) given IM to induce dissociative anesthesia, followed by an IA injection
of 4 mg

131

I-rhPRG4 into the right knee. Flexion and extension of the right knee was performed

for 5 minutes post injection to ensure distribution of the 131I-rhPRG4.

7
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Tissue Harvesting and Preparation of Counting for Radioactivity Decay
Minipigs were euthanized at specific timepoints determined a priori illustrated in Fig 1 for
collection of tissues. Animals were euthanized by sedation with acepromazine and ketamine (as

above) followed by an overdose of pentobarbitol (100 mg/kg) IV via an ear vein. Right knees

were collected and SF was collected by aspiration. Upon gross dissection, cartilage surface
irrigation with 5 ml of PBS was performed and recovered. Partial thickness cartilage specimens
were excised from the medial femoral, medial tibial, lateral femoral, lateral tibial and patellar
surfaces. The medial and lateral menisci were collected. Anterior and posterior synovial lining

tissue, the pre-femoral lymph node, liver tissue and urine was also collected. Each of these
tissues were weighed, and then held at 4˚C while transported to McMaster University for
gamma counting within 3 hours of collection. A 24 hour urine collection was not conducted since

metabolic cages were not available.
Gamma Counting

The amount of 131I-rhPRG4 remaining in tissues was measured using a Wizard 3 1480 Automatic
Gamma Counter (Perkin Elmer, Woodbridge, ON, Canada). The gamma radiation counts were
then converted to rhPRG4 amounts based on the counts of a non-injected 131I-rhPRG4 standard
solution that was stored at McMaster University.

Prior Yucatan Minipig Cartilage, Meniscus and Synovium Total Mass Measurements
Four previously frozen unoperated Yucatan mini-pig left knee joints were disarticulated into
separate segments that included the distal femur, proximal tibia and patella. The entire joint

capsule was kept attached to the patella for subsequent soft tissue studies. The medial and lateral
8
This article is protected by copyright. All rights reserved

menisci were excised and weighed using an analytical balance. A GE eXplore Locus CT scanner
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(Schenectady, NY) was used to image the bone and soft tissue segments in humidified air. An 18

minute long 45 micron resolution protocol32 resulted in 720 slices comprised of isotropic voxels.
Slices were compiled and subsequently realigned in a true frontal plane. Image manipulation and
analysis was done using Microview 2.5 (Parallax Innovations, Ilderton, ON, Canada). Articular
cartilage volume and surface area were measured by outlining cartilage in thresholded frontal plane
image slices using the advanced region of interest (ROI) (spline) tool. Three-dimensional ROIs
were compiled and voxel counts from isosurface projections were used in calculation of area and
volume (Figure 2). Separate ROIs were created for the medial and lateral condyles, medial and
lateral tibial plateaus and patella cartilage plates. Cartilage mass was calculated by volume x 1.1

gm/cc based on volume displacement trials of porcine articular cartilage.

Synovial membrane mass was calculated by first identifying the geographic distribution of
synovial membrane in normal mini-pig knees as determined by microCT imaging of the entire
Lugol’s iodine-stained joint capsule in Ringer’s solution. Synovial tissue mass was determined
from harvested normal unoperated joints by dissecting synovial fronds from the underlying joint
capsule while the tissue was immersed in Ringer’s solution which allowed the synovial tissue to
float and adopt a three-dimensional villus profile. Areas of synovial lining tissue were weighed
after collection using an operating microscope and micro-instruments.

9
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Pharmacokinetic Calculations

The individual knee tissue concentrations of total radioactivity were normalized to a gram of tissue
and the total amount of rhPRG4 per tissue was calculated using the total mass of individual knee
tissues. The percent of rhPRG4 dose detected at each time point: zero (10 mins), 24, 72 hrs, 6, 13
and 20 days was calculated after a single IA dose of 131I-rhPRG4 of 4 mg/knee. The area under the
blood concentration-time curves (AUC) was calculated using the trapezoidal rule up to the last
measured concentration, Clast. To the latter AUC was added Clast/β to calculate AUC0-∞. The
parameters were determined for each individual animal and their average was calculated.

The total radioactivity counts of 131I-rhPRG4 (expressed as percent of total dose) at each time point
was calculated and fitted to two compartment model using Phoenix WnNonlin version 64
(Pharsight Corporation, Sunnyvale, CA, USA). The percent of total dose in cartilage, menisci and
synovium at different time points were fitted using least square regression with either 1/y or 1/y2

weighting factors to two compartmental model (Ct = Ae-αt + Be-βt) where Ct counts (as % dose) at
time t were weighted as the inverse of the Ct. Pharmacokinetics parameters of blood concentrations
of 131I-rhPRG4 (µg equivalent/mL) at each time point were calculated for each individual animal
after fitting the concentrations time curve to a two compartment model.
Western Blotting of PRG4 in SF and Joint Lavage Samples, and IL-1 ELISA

SDS-PAGE electrophoresis of undiluted samples on pre-cast 4-12% gradient gels (ThermoFisher
Scientific, Waltham, MA) and transfer to nitrocellulose was performed as described previously31.
Polyclonal antibody 1752 (ABPRO, Woburn, MA, USA) that reacts with the epitope
FESFERGRECDCDAQCKKYDK in the N-terminus of PRG433 was used at 1:1000 dilution
with 5% bovine serum albumin in PBST. Membranes were incubated with IRDye goat anti10
This article is protected by copyright. All rights reserved

rabbit IgG at 1:10,000 dilution for 1 hr at RT with shaking. Levels of IL-1 were measured on
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undiluted samples using a commercially available kit #PLB00B (R&D Systems, Minneapolis,
MN).
Blot Imaging and Densitometric Analysis
The blots were imaged with LI-COR Odyssey (LI-COR Biosciences, Lincoln, NE, USA) imaging
system with 800 or 700 CW according to manufacturer’s instruction. NIH image J
(https://imagej.nih.gov/ij/) was used for chemiluminescent band analysis (NIH, Bethesda, MD,
USA). Lanes were compared to a -actin standard and densitometrically normalized to a LI-COR
anti-β actin monoclonal antibody #926-42210. Densitometric standards were established by

imaging known amounts of rhPRG4 solubilized in normal porcine SF in different lanes of a blot
simultaneously. The detectable limit of rhPRG4 concentration was 10 g/ml.

Tissue Processing and Immunohistochemistry
Following gamma counting at the time of sacrifice, all knee joint tissues were fixed in 10%
formalin (PROTOCOL™, Fisher, Waltham, MA, USA). After 4 months to allow for sufficient
radioactive decay, samples were transported under United States Department of Agriculture permit
#132894. Samples were decalcified using 0.48 M EDTA, with adjusted pH of 7.1 with ammonium

hydroxide at 4°C. Embedded tissues were sectioned with a thickness of 10µm.
Sections were probed for surface accumulation and nascent expression of PRG4 within
chondrocytes using monoclonal antibody 9G331 (EMD Millipore; Darmstadt, Germany) which

reacts with the mucin domain of PRG4 using methods described previously25.

11
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Statistical Methods
Data were reported as mean ± standard deviation (SD) unless otherwise indicated. Descriptive
statistical analyses were performed using Prism 6 software (GraphPad, La Jolla, CA).
RESULTS
Study Conduct and Tissue Recovery
This uncontrolled study was conducted over 16 months in groups of 6, 12 and 3 porcine due to
animal availability. No adverse events occurred. Three animals were removed from the analysis
since they evidently did not receive IA rhPRG4 since radioactivity was undetected in the SF
from euthanized animals #39 and #91 at time point 10 minutes (time zero) and animal #86 at 24

hrs. In these animals, the principal radioactivity was recovered in either the proximal lymph node

or in the urine. Across the remaining 18 porcine at the time point of 10 mins, an average of
32.0% of dose was located in the cartilage and synovial knee tissues, 20.7% in synovial fluid,
1.2% on the ACL stump, 0.09% in the proximal lymph node, 9.5% in liver and 35.4% in the
lavage of the joint surfaces. Another lavage at 24 hrs only recovered 0.064% of dose suggesting

that a majority of the rhPRG4 was present in the SF or fully adherent to articular and synovial
surfaces. rhPRG4 was primarily excreted in the urine and was not significantly present in
adjacent lymph nodes in the 18 animals that received the IA injection correctly. Tissue

recoveries were not conducted for the first group of 6 animals allocated to time points 6,13 and
20 days post IA injection.

12
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Elimination of I131-rhPRG4 and Akaike Information Criterion (AIC) model fitting
Figure 3a shows the distribution and elimination of the percent dose of total radioactivity of the
knee which included all joint tissues, the lavage fluid and SF which in aggregate accounted for

89.4% of total dose. At 24 hrs after injection, 7.7% of the total instilled dose of 131I-rhPRG4 is
resident in the joint. Radioactivity is still present on days 13 and 20 suggesting that the complete

elimination of 131I-rhPRG4 is delayed. A two-compartment elimination model, using AIC, best
fit these data from the 18 porcine using counts from cartilage, meniscii and synovial tissue which

accounted for 33% of dose (Figure 3b). The porcine knee joint modeled with this twocompartment elimination model shows that the  half-life (t1/2phase is 11.28 hours and the t1/2

is 4.81 days long (Figure 3c and 3d).

Different modeling permutations of tissue counts from cartilage, meniscii and synovium, SF and
cartilage surface lavage were analyzed in Table 1 to identify tissues and/or fluids with maximal
t1/2 and t1/2. Permutations that included counts from cartilage lavage had a shorter t1/2 and did
not appear different than those containing cartilage tissues. Table 1 also indicates that t1/2 and
t1/2 values did not lengthen when considering only counts from cartilage, meniscii and synovial

tissue. Permutations that included SF counts maximized t1/2 to a maximal time of 28 days.
Calculation of K12 and K21 (Table 1) for cartilage, meniscii, synovial tissues and SF shows that
K21 > K12 for SF and synovium indicating that 131I-rhPRG4 was more likely to reside in SF or

on synovial surfaces. Cartilage and other tissues, with and without lavage all showed K21< K12
indicating that 131I-rhPRG4 was more likely retained on cartilage and meniscii. The long SF t1/2
value of 28 days and the K21/K12 ratio greater than unity support that SF is the reservoir for

PRG4.
13
This article is protected by copyright. All rights reserved

The blood concentrations of total radioactivity of 131I-rhPRG4 also showed a two-compartment
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profile with the highest concentrations shown at 10 minutes after dose (5.8±7.1µg
equivalent/mL). Lubricin was eliminated from the systemic circulation with a mean total
clearance of 21.54±4.18 mL/day/kg and a t1/2of 6.48 hours and t1/2 of 15.88 days. However,
the mean systemic exposure represented by total area under the blood concentrations time curve
(AUC 0-∞) was < 15% of the total area under the knee tissue concentrations curve of 131I-rhPRG4
(3.38±0.65 vs 26.32±0.47 µg equivalent day/mL). Following the IA administration of 131IrhPRG4 9.5% of total dose was found in the liver after 10 mins which decreased to 5.6% and
0.36% after 1 and 13 days, respectively. However, no radioactivity was detected on day 20.
Tibial-femoral Joint Compartmentalization of rhPRG4
Tibial cartilage and synovial membrane surfaces appeared to contain relatively larger amounts of
131

I-rhPRG4 at time 0 (Figure 4a). By day 1 synovial surfaces appeared to contain relatively

larger amounts of 131I-rhPRG4. By day 13 and 20, cartilage surfaces showed the greatest relative
amounts of 131I-rhPRG4 (Figure 4b). In comparing the proportion of 131I-rhPRG4 localizing to

the femoral and tibial cartilage in medial and lateral joint compartments we observed that
initially 131I-rhPRG4 localized more to the tibial cartilage surfaces and equally to both
tibiofemoral joint compartments (Figure 5a). Towards the end of the concentration-time profiles

studied at day 20, the lateral joint compartment and femoral cartilage retained a greater relative
percentage of recoverable 131I-rhPRG4 (Figure 5b).

14
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Cartilage Surface Lavage and Western Blots of rhPRG4 and Porcine PRG4
Both rhPRG4 and native porcine PRG4 were detected on Western blots of recovered cartilage
surface lavages (Figure 6a). The different molecular weights of detectable rhPRG4 (apparent
MW~300 kDa) and porcine PRG4 (MW~180 Kda) enabled the densitometric measurement of

rhPRG4 relative to porcine PRG4. Figure 6a shows that rhPRG4 was detectable up to 13 days after
IA injection. Semi-quantitative analysis in Figure 6b indicates that rhPRG4 levels are initially high
at time zero, decreased at 24-72 hrs, and were near zero by day 20. By contrast, the relative
amounts of porcine PRG4 increased from day 3 to day 13.

Immunohistochemistry of Total PRG4, and IL-1 Levels
The observation that the amount of rhPRG4 was decreasing as the relative amount of native PRG4
increased is supported by immunohistochemistry using mAb 9G3 for total PRG4 on the articular
surfaces (Figure 7). The total detectable amount of surface PRG4 diminished from day 1 to day
20. Near the time of IA delivery at 10 minutes there is some immunoreactivity at the articular

surface but significantly less than cartilage from animals sacrificed after 24 hours likely indicating
that sometime was needed for rhPRG4 to interact with the articular surface and colocalize with
native porcine PRG4. Superficial zone chondrocyte immunopositivity for PRG4 became more
observable at days 6 and 13 suggesting that endogenous production of porcine PRG4 was increased
during the time course of the study. IL-1 at time 0 in surface lavage was 319.8±365.8 pg/ml (N=3)
and 74.8±81.8 pg/ml in SF (N=3). At 24 hrs two porcine had SF levels of 88.7 and 34.8 pg/ml. IL1 levels were below detectable limits for porcine SF and lavaged samples over the remaining
time points with the exception of 34.1 pg/ml for a SF sample at 20 days.

15
This article is protected by copyright. All rights reserved

DISCUSSION
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Recombinant human PRG4 is surface active and recapitulates the ability of natural lubricin to coat
biological surfaces and provide both anti-adhesive34-36 and lubricating activity29. Lubricin forms
end-grafted brushes37-39 that provide steric hindrance against a like-covered apposing articular
surface and structures hydration shells vis-à-vis extensive O-linked glycosylations40; 41 that exist
in the mucin domain. Lubricin interacts with biological and non-biological surfaces, and has a
preponderance to interact with hydrophobic surfaces42; 43. The results support a partitioning of
lubricin that is cartilage bound and unbound within the SF. Partitioning provides a reservoir of
lubricin44 that can replace lubricin that is sacrificially worn away during articulation45. This is

supported by the high amounts of

131

I-rhPRG4 recovered from cartilage surfaces with irrigation

soon after IA delivery, and from SF recovered from closed joint needle aspiration; suggesting that
131

I-rhPRG4 was tethered but not fully adherent to the cartilage surface. These observations

support the two-compartment pharmacokinetic elimination model. The t1/2of 11.28 hrs reflects
rhPRG4 that is primarily metabolized in SF which is contained within the diarthrodial joint
structure. Comparatively less radiolabel was detected in the blood, liver, urine or proximal lymph
node after IA injection. The t1/2 of 4.81 days is reflective of lubricin that was likely cartilage,
meniscii and synovial surface bound. These estimates are driven by the tissues only model in Fig
3b which accounted for 33% of total radioactivity. Both half-lives are in fair agreement with a

prior effort24 in medial meniscectomized rat knees that were injected with 131I-truncated rhPRG4
3 weeks later. In that study, a three-compartment model best fit the PRG4 concentration-time
profiles and reported ,  and  half-life estimates of 4.5 hrs, 1.5 days and 2.1 weeks respectively.

We were unable to fit a three compartment model with our data which may be due to lack of
sampling times past 20 days. Considering counts from the SF exclusively lengthened t1/2 to 28
16
This article is protected by copyright. All rights reserved

days which is in agreement with the earlier rat study24. The long t1/2 in SF and the fact that K21 >
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K12 (Table 1) suggests that SF is the reservoir for PRG4 and that rhPRG4 may emulate its
biophysical and physisorptive activity.

In comparing these two studies it is important to realize that the present effort used a larger joint
and a full-length recombinant human lubricin that was 1404 amino acids long which may have a

longer residence time. The present study was accomplished with an arthroscope to transect the
ACL ligament, thus reducing tissue injury associated with an arthrotomy. Use of a minimally
invasive surgical technique, and delay in treatment, are approaches that recapitulate current clinical
practice. We also observed in Figs 4-5 that the tibial cartilage surfaces showed a disproportionate

loss of rhPRG4 over time compared to the femoral cartilage. Since cartilage thinning following
ACL injury is predicted to be more severe in tibial cartilage and in the medial compartment46, we
posit if friction-induced metabolic changes in cartilage can confound rhPRG4, PRG447 and Prg448
in serving its chondroprotective role.

The introduction of rhPRG4 into an injured joint may have several positive consequences. Local
PRG4 expression is upregulated by physical activity49. The combination of compression and shear
in vitro has been observed to increase expression of PRG4 by several laboratories45; 50; 51. Human
recombinant PRG4 also displays anti-inflammatory properties through inhibition of the innate
immunity receptors, TLR2 and TLR4 52; 53. Suppressing inflammation by itself may play a positive

role since incubation of bovine cartilage explants with IL-1 in vitro has been shown to suppress
native PRG4 expression25. Figures 6 and 7 together support the notion that rhPRG4 densely coated
cartilage surfaces on days 1 and 3 post injection and subsequently diminished over time. Some of
17
This article is protected by copyright. All rights reserved

the rhPRG4 may have penetrated into the cartilage25 which is supported by the continued
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radioactivity of cartilage despite surface irrigation. By post-injection days 6 and 13 resident
porcine chondrocyte PRG4 expression was qualitatively supported by chondrocyte
immunoreactivity (Figure 7). We posit that the presence of rhPRG4 served to restore the
expression of native PRG4 in an inflammatory environment that was down trending as a result of
the ACL transection surgery 5 days previous.

The cartilage surface area of the human knee is 121 cm2 54 and 277 cm2 55 for the synovium. The
cartilage surface area in the Yucatan mini-pig was 32.4 cm2. Availability for rhPRG4 binding is

thus allometrically 3.7 times larger in the human joint. The 4 mg dose used in the present study
was effective in mitigating PTOA in the same porcine species following DMM when used weekly
over three weeks12. A dose escalated single injection study is planned and supported by a recent
study in the rat where a single 260 g/kg IA rhPRG4 dose, was equally effective to smaller

repetitive doses10. Extrapolating the distribution of availability based on cartilage surface area
alone in the human knee from the mini-pig knee leads to the conclusion that a 14.8 mg dose of
rhPRG4 provided shortly after an acute knee injury may be enough to achieve both cartilage
surface coverage and bioavailability from SF. This calculation does not consider the much larger

synovial membrane area. The synovium demonstrated considerable radioactive counts suggesting

that rhPRG4 was present. Uptake of biomaterials and biologics occurs across synovial villi26, and
is a source of PRG4 synthesis56 that is under autoregulation52. The present study did not involve

HA to take advantage of possible synergistic effects with PRG418;

30; 57-60

. We observed

immunopositivity for PRG4 only in the synovium at time 0 (data not shown) but in the absence of
a non-injected surgical control animal we cannot conclude if this represents a lack of porcine PRG4
18
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contribution from the synovium.

Limitations include the application of rhPRG4 early in a PTOA animal model in which disease
progression was not studied histologically. A relatively low amount of joint cavity irrigation was
used during arthroscopy. Irrigation has been shown to eliminate the resident lubricin in the bovine
joint61. The lower amounts of irrigation used for this surgical injury may have resulted in the

rhPRG4 mixing with resident porcine PRG4 which could impact its bioavailability. By contrast, 5
days after surgery also likely diminished resident porcine PRG4 levels25. However, an increase in
native PRG4 expression from the synovium as observed in an equine OA model, 20 days following
surgery62 has not been excluded. Our study was conducted cumulatively across 3 groups of animals

due to logistical challenges. Tissues that were recovered in the first group were not retained for
later histological analysis; a limitation corrected for most of the animals. Finally, this study was
conducted in quadrupeds that have a different gait pattern than humans and were not skeletally
mature. However, ACL transection recapitulates a common joint injury in adolescent humans.
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Legends
Figure 1. Timeline of Yucatan mini-pig pharmacokinetic (PK) study of intra-articular (IA) I131rhPRG4 at Day 0 (D0) following ACL transection 5 days prior (D-5). The remaining number of
porcine following each tissue harvest time point is illustrated. The first harvest involving 5 animals
occurred at 10 mins following IA (D0+10m) which served as time zero in PK calculations.
Sequential tissue harvests following IA were conducted at 24 hrs (D1), 72 hrs (D2), 6 days (D6),
13 days (D13) and 20 days (D20). At each time point synovium and cartilage collected from each
joint compartment and both condyles were weighed and counted for radioactivity across 21
animals. Samples of SF, blood, liver and proximal lymph node were also collected and counted.
Three animals were removed from the analysis as they did not receive IA injection correctly and
demonstrated very high lymph node radioactivity.
Figure 2. Cartilage surface area and volume analysis by microCT. Four previously frozen
unoperated Yucatan mini-pig left knee joints served as controls to determine the surface area and
volume of each cartilage surface from the patellofemoral joint and both compartments of the
tibiofemoral joint. The product of the tissue density multiplied by the representative cartilage
volume from each area was used as the tissue mass denominator in normalizing gamma counts per
tissue weight to determine the total amount of I131-rhPRG4 resident in each cartilage surface. Mean
± SD is reported.

Figure 3. Least squares fitting model and Akaike Information Criterion (AIC) of the percent of
total dose of I131-rhPRG4 in recovered knee tissue counts including lavage and aspirated SF across
time points at 10 minutes, days 1,3,6,13 and 20 for 18 porcine following intra-articular I131rhPRG4 delivered 5 days after ACL transection. A) 98% of the total dose at 10 minutes (day 0)
was accounted for across the 6 time points by least squares elimination profile which did not
conform to a predicted AIC two-compartment model. B) 33% of the total dose at 10 minutes was
accounted for by considering only knee tissue counts (excluding lavage and aspirated SF) which
conformed to an AIC two-compartment model. D) Akaike Information Criterion parameter tables
showing AIC t1/2 estimates in days, and coefficient of variation (CV%). Error bars are mean ± SE;
N=3 at each sampling time.
Figure 4. Knee joint tissue concentrations of I131-rhPRG4 at 10 minutes (day 0), days 1 and 3 (A),
and days 6,13 and 20 (B). Tibial cartilage and synovial membrane surfaces appeared to contain
relatively larger amounts of I131-rhPRG4 at 10 minutes and remained greater by days 1,3 and 6 for
25
This article is protected by copyright. All rights reserved

Accept e d Article

synovial surfaces. By day 13 and 20, cartilage surfaces showed greater relative amounts of I131rhPRG4. Abbreviations: Medial femoral condyle (MFC), medial tibial plateau (MTP), lateral
femoral condyle (LFC), lateral tibial plateau (LTP), medial meniscus (MM), lateral meniscus
(LM), synovial membrane anterior compartment (SMAC) and synovial membrane posterior
compartment (SMPC). Error bars are mean ± SE; N=3 at each sampling time.
Figure 5. Percent of recovered total knee I131-rhPRG4 across time points at 10 minutes (day 0),
days 1,3,6,13 and 20 in 18 porcine following intra-articular I131-rhPRG4 delivered 5 days after
ACL transection. (A) Comparison of total femoral and tibial cartilage and (B) total medial and
lateral cartilage. Initially I131-rhPRG4 localized more to the medial joint compartment and tibial
cartilage surfaces. Towards the end of the concentration-time profiles studied at day 20, the lateral
joint compartment and femoral cartilage retained a greater relative percentage of recoverable I131rhPRG4. Error bars are mean ± SE; N=3 at each sampling time.

Figure 6. Densitometry of rhPRG4 (MW~300 kDa) and native porcine PRG4 (MW~180 kDa)
bands on Western blots of joint surface lavage in 12 of the 18 porcine following intra-articular I131rhPRG4 delivered 5 days after ACL transection. A) Samples at 10 minutes (day 0) (N=3),1 (N=3),
3 (N=2), 6 (N=1), 13 (N=2) and 20 (N=1) were analyzed on SDS-PAGE and transferred to
nitrocellulose 4 months following recovery to allow sufficient radioactive decay. Blots were
probed with polyclonal antibody 1752 and densitometry was performed in triplicate and
normalized against a 10 g/ml preparation of rhPRG4. B) rhPRG4 decreased over time and was
detectable up to 13 days later, whereas porcine PRG4 increased over that same interval. Error bars
are mean ± SD.
Figure 7. Immunohistochemistry of total PRG4 comprising injected rhPRG4 and native PRG4
across representative porcine at 10 minutes (day 0), days 1,3,6,13 and 20 following intra-articular
I131-rhPRG4 delivered 5 days after ACL transection in 18 porcine. Cartilage surface
immunoprobing with monoclonal antibody 9G3 was counterstained with DAPI in sections from
the two apposing surfaces from medial and lateral joint compartments. Cartilage surface staining
was qualitatively most intense at day 1 and 3, and least intense by day 20 which is similar to
untreated and historical control porcine cartilage. Chondrocyte positivity for PRG4 (white arrows)
appeared most intense at day 6 and may be indicative of renewed native expression of porcine
PRG4.
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Table 1. Summary of Fitted Two Compartment Model by Tissue and Fluid Type
t1/2,
(Days)

t1/2,β
(Days)

K12
(Day-1)

K21
(Day-1)

Synovial Fluid

0.26

28.07

0.034

0.062

Anterior & Posterior Synovium

0.59

3.09

0.104

0.253

Cartilage + Meniscii

0.36

7.10

0.443

0.149

Cartilage + Meniscii + Cartilage
Lavage

0.22

6.19

0.450

0.130

Cartilage + Meniscii + Cartilage

0.33

4.40

0.299

0.186

0.47

4.81

0.252

0.179
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Tissue(s) and/or Synovial Fluid or
Lavage

Lavage + Anterior & Posterior
Synovium
Cartilage + Meniscii + Anterior &
Posterior Synovium
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30
This article is protected by copyright. All rights reserved

Accept e d Article

Figure 4 (A)
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Figure 4(B)
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Figure 5(A)
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Figure 5(B)
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Figure 6(A)
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Figure 6(B)
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Figure 7
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